Inclusion Criteria

Inclusion criteria:

- Patients willing to sign informed consent prior to entry into the study,

- Patients who have been prescribed a Taxotere based regimen,

- Patients who have not yet started with the first Taxotere treatment,

- Patients with a histological diagnosis of one of the following solid tumours: breast
cancer, non-small cell lung cancer (NSCLC), ovarian cancer, prostate cancer, gastric
cancer or head and neck cancer.

Exclusion criteria:

- Patients who are enrolled in another clinical study,

- Pregnant and/or breastfeeding patients, including women of childbearing potential not
willing to use medically acceptable methods of contraception,

- Patients with severe liver impairment,

- Patients with severe renal function impairment,

- Patients with a known hypersensitivity to Granocyte 34 or its constituents,

- Patients with a history of severe hypersensitivity reactions to Taxotere or
Polysorbate 80,

- Patients with a baseline neutrophil count of < 1500cells/mm3,

- Patients on other drugs that are contra-indications for the use with Taxotere,

- Patients on con-current radiotherapy.

The above information is not intended to contain all considerations relevant to a
patient's potential participation in a clinical trial.